XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkey - Wikidata - awgldk - TriplyDB

XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkey

XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkey

http://www.wikidata.org/entity/Q34321054

about

Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study Modifications of antiepileptic drugs for improved tolerability and efficacy The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential Impact of Data Imputation Methodology on Pain Assessment over 24 Hours in a Randomized, Placebo-Controlled Study of Gabapentin Enacarbil in Patients with Neuropathic Pain Associated with Postherpetic Neuralgia.Monocarboxylate transporter-mediated transport of gamma-hydroxybutyric acid in human intestinal Caco-2 cells Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine Role of monocarboxylate transporters in drug delivery to the brain.Gabapentin enacarbil - clinical efficacy in restless legs syndrome Gabapentin enacarbil (XP13512/GSK1838262) as an alternative treatment to dopaminergic agents for restless legs syndrome.Restless legs syndrome: a comprehensive overview on its epidemiology, risk factors, and treatment.Gabapentin enacarbil: in patients with restless legs syndrome.The use of gabapentin enacarbil in the treatment of restless legs syndrome.Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin.A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome.Organic carbamates in drug design and medicinal chemistry A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors.Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).Role of gabapentin enacarbil XR in restless legs syndrome Identification, design and biological evaluation of heterocyclic quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).Strategies to improve oral drug bioavailability.New antiepileptic drugs that are second generation to existing antiepileptic drugs.Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid.A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome.Prodrugs for amines.Formed and preformed metabolites: facts and comparisons.Gabapentin enacarbil extended release for the treatment of postherpetic neuralgia in adults.Nanotechnology for delivery of drugs to the brain for epilepsy.Gabapentin enacarbil for the treatment of moderate to severe primary restless legs syndrome (Willis-Ekbom disease): 600 or 1,200 mg dose?A comparison of the metabolism of clopidogrel and prasugrel.Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach.ADMET considerations for restless leg syndrome drug treatments.ADMET considerations when prescribing novel therapeutics to treat restless legs syndrome.The Effect of Gabapentin Enacarbil on Quality of Life and Mood Outcomes in a Pooled Population of Adult Patients with Moderate-to-Severe Primary Restless Legs Syndrome.Pharmacological Management of Restless Legs Syndrome and Periodic Limb Movement Disorder in Children.Different doses of gabapentin formulations for postherpetic neuralgia: A systematical review and meta-analysis of randomized controlled trials.The Effect of Gabapentin Enacarbil on Pain Associated with Moderate-to-Severe Primary Restless Legs Syndrome in Adults: Pooled Analyses from Three Randomized Controlled Trials.Pharmacokinetic/Pharmacodynamic Relationship of Gabapentin in a CFA-induced Inflammatory Hyperalgesia Rat Model.Discovery of MK-8970: an acetal carbonate prodrug of raltegravir with enhanced colonic absorption.Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil.Gabapentin for the treatment of alcohol use disorder.

P2860

Q24603670-5244D23D-8D9B-49D3-A414-978F1976D269 Q24651951-8F1DCBB9-5EF8-491D-974A-B1B0DB1188AA Q26781422-EA69499D-F12B-42D7-A8C7-D42695871621 Q31040173-DFE8E6FA-0132-4EF2-B570-665CAADF3712 Q33714582-645C0754-15F4-4FEF-8E49-1B8D2A5D066D Q33795067-9EC9EA5A-48BA-4CB8-9DA4-032DEBD05DBB Q33854710-D7417843-E982-4DF2-AE73-4417D2730580 Q33868110-263722B7-3975-4C8A-9010-FF3220A005FF Q34125935-E8AA863F-478F-4B2C-8B9D-B1611A32055E Q34228792-7E8F5D1E-5FB6-4E50-927C-37CE4C006FD5 Q34313624-6806A373-236E-43C7-865E-BDE27E976697 Q34409544-6FB3664F-2DBF-42EC-8AB9-CE6FF24C617A Q34841404-6BFD4CC8-DC1D-4EDB-A130-D76AD812BE14 Q35042278-A4120521-96D9-4A0D-BAD1-016769CE6CDF Q35365543-141B9F00-EBED-4062-AF4C-6FEF64F55B92 Q35545279-92671335-7BAC-4037-BFE8-164453EB6758 Q35814421-96705AC8-4F98-4431-BB8B-C0B973B9B3C1 Q35940214-10B9A4AC-82E0-405F-9FD0-56E2F7511F93 Q35958086-60B4489F-2FA2-4907-AE4D-4AC71C635136 Q36316751-89C17467-282A-4EA4-A16D-81F2F02D6B22 Q36491829-DB74EB8B-A448-4FAB-A750-E5B1DE0ADE19 Q36952136-1617CD42-B1ED-498F-86B7-67860E23DD01 Q37083130-FAD0D814-543B-40B7-BCBD-8C1C1598F3FB Q37157240-B7C6C7AC-9CD5-4BA1-8C02-F5A481AB13C2 Q37277366-688385AB-BBB3-4875-869E-1BB528E38CDE Q37388380-79C320D1-8D5D-412F-B92E-0E9B4DBD7282 Q37426991-701B61E5-9677-49EE-827E-A3C7286ECDC6 Q37577779-8D43EEBB-D55E-4FAC-ADBF-729A816CD3E2 Q37788682-48013311-A10A-4B53-A441-1A4B0EA5C613 Q38019048-98747B39-49DF-4787-AFE4-051072468D25 Q38027180-33CAE1EE-0367-4DE2-BF09-851A371D3C46 Q38242390-E65005B3-F163-40F7-8623-2C4E97092B9D Q38393782-80EBBF75-92F9-40A7-8B44-BEEAF30D15D9 Q38612985-8ABE697B-2F7F-4B6A-A7CF-718647E1BC57 Q38995448-3F9456C8-BB38-4FA8-A967-023051312564 Q39838178-76C0F767-7A01-48DA-8F05-0C5EA3F34D45 Q40094164-3CC52E6C-C0A4-4BAB-BFB6-7D8A409BC2CE Q41621096-59346A6C-21D3-4736-8920-C9A26FE99526 Q46153517-4C2DD45A-BD79-4CF7-B61C-CACF65D74FAB Q47309377-35E89410-24B0-4FE1-97E6-5E0B612A983E

P2860

XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkey

http://www.wikidata.org/entity/Q34321054

description

2004 nî lūn-bûn

@nan

2004 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

name

XP13512 [(+/-)-1-([(alpha-isob ...... gabapentin in rats and monkey

@ast

XP13512 [(+/-)-1-([(alpha-isob ...... gabapentin in rats and monkey

@en

XP13512 [(+/-)-1-([(alpha-isob ...... gabapentin in rats and monkey

@nl

type

label

XP13512 [(+/-)-1-([(alpha-isob ...... gabapentin in rats and monkey

@ast

XP13512 [(+/-)-1-([(alpha-isob ...... gabapentin in rats and monkey

@en

XP13512 [(+/-)-1-([(alpha-isob ...... gabapentin in rats and monkey

@nl

prefLabel

XP13512 [(+/-)-1-([(alpha-isob ...... gabapentin in rats and monkey

@ast

XP13512 [(+/-)-1-([(alpha-isob ...... gabapentin in rats and monkey

@en

XP13512 [(+/-)-1-([(alpha-isob ...... gabapentin in rats and monkey

@nl

P1433

Q34321054-8E0B7F0D-4091-4E2D-9815-1E6DA2A68B3F

P1476

Q34321054-28F4CAB1-98F2-45BF-ABC4-2FCFD8714EE6

P2093

Q34321054-0DDBB683-4C7A-4FDC-886F-92174C969AD2

Q34321054-0F970C44-0964-46DD-9AAB-CD11B0CD8AF6

Q34321054-79F1EF3C-5299-4C8F-85B6-408EF4A03B28

Q34321054-840637AE-275A-451E-A3D9-20BB9AC0E0AE

Q34321054-89F4F048-6632-4A37-A19A-B6985615982B

Q34321054-8A3FE306-BA4B-47CE-8531-0BDBD1AEE8DF

Q34321054-8FB7EA2F-A552-4F7F-8113-CC53F97DFC79

Q34321054-9DBAE9D1-9D3D-409F-B931-E6D23001EB74

Q34321054-A2DC8611-AB77-4D91-9B57-C272355A9BDF

Q34321054-BA0024B2-32A3-4ECD-A90F-3AB405F67FFB

P304

Q34321054-DF316A8E-53CC-4623-9900-E1C9D7695BCD

P31

Q34321054-9909B844-A222-4864-A4AE-45C074B8D9CE

P356

Q34321054-B8802511-25C1-4D58-87A0-00F2A8F4F1DA

P407

Q34321054-47DE888D-A077-4B03-929F-33D9455FE26A

P433

Q34321054-66E2CD7E-FCE9-4223-8644-F6EE541E0701

P478

Q34321054-88B3284C-B152-4389-B280-B5D6D84D9A3C

P577

Q34321054-BC482EC5-8152-4B26-9F8C-CA743253F8FA

P5875

Q34321054-95FACC79-C48D-49DD-A49B-66CFE6AF648A

P698

Q34321054-7087E119-C400-40C0-8162-F96368627719

P921

Q34321054-097B2F67-C2FB-4902-BCDD-E58BD88F33DB

P356

JPET.104.067959

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

XP13512 [(+/-)-1-([(alpha-isob ...... gabapentin in rats and monkey

@en

P2093

Allan Torneros

http://www.w3.org/2001/XMLSchema#string

Fenmei Yao

http://www.w3.org/2001/XMLSchema#string

Jenny Estrela

http://www.w3.org/2001/XMLSchema#string

Joan Zou

http://www.w3.org/2001/XMLSchema#string

Josephine De Vera

http://www.w3.org/2001/XMLSchema#string

Kenneth C Cundy

http://www.w3.org/2001/XMLSchema#string

Lin Bu

http://www.w3.org/2001/XMLSchema#string

Mark A Gallop

http://www.w3.org/2001/XMLSchema#string

Payal Shirsat

http://www.w3.org/2001/XMLSchema#string

Ronald W Barrett

http://www.w3.org/2001/XMLSchema#string

P304

324-333

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/JPET.104.067959

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

311

http://www.w3.org/2001/XMLSchema#string

P577

2004-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8560180

http://www.w3.org/2001/XMLSchema#string

P698

15146029

http://www.w3.org/2001/XMLSchema#string

P921